Millendo Therapeutics Inc. (MLND) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Comparing side by side

Both Millendo Therapeutics Inc. (NASDAQ:MLND) and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Millendo Therapeutics Inc. N/A 0.00 79.77M -12.29 0.00
Galmed Pharmaceuticals Ltd. 2.31M 77.26 9.79M -0.67 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Millendo Therapeutics Inc. and Galmed Pharmaceuticals Ltd.


Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Millendo Therapeutics Inc. 0.00% -54% -48.7%
Galmed Pharmaceuticals Ltd. -423.81% -18.6% -17.5%

Risk and Volatility

A 3.31 beta means Millendo Therapeutics Inc.’s volatility is 231.00% more than S&P 500’s volatility. Galmed Pharmaceuticals Ltd. has a 2.71 beta and it is 171.00% more volatile than S&P 500.


12.6 and 12.6 are the respective Current Ratio and a Quick Ratio of Millendo Therapeutics Inc. Its rival Galmed Pharmaceuticals Ltd.’s Current and Quick Ratios are 43.3 and 43.3 respectively. Galmed Pharmaceuticals Ltd. has a better chance of clearing its pay short and long-term debts than Millendo Therapeutics Inc.

Analyst Ratings

Millendo Therapeutics Inc. and Galmed Pharmaceuticals Ltd. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Millendo Therapeutics Inc. 0 0 0 0.00
Galmed Pharmaceuticals Ltd. 0 0 3 3.00

Competitively Galmed Pharmaceuticals Ltd. has an average target price of $33.75, with potential upside of 298.94%.

Insider and Institutional Ownership

The shares of both Millendo Therapeutics Inc. and Galmed Pharmaceuticals Ltd. are owned by institutional investors at 60.9% and 38.3% respectively. Millendo Therapeutics Inc.’s share held by insiders are 0.1%. Comparatively, insiders own roughly 21.61% of Galmed Pharmaceuticals Ltd.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Millendo Therapeutics Inc. 9.51% 19.75% 20.71% 11.56% -10.05% 57.86%
Galmed Pharmaceuticals Ltd. 4.55% 7.46% -1.39% -35.7% 61.29% 24.45%

For the past year Millendo Therapeutics Inc.’s stock price has bigger growth than Galmed Pharmaceuticals Ltd.


On 8 of the 10 factors Galmed Pharmaceuticals Ltd. beats Millendo Therapeutics Inc.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.